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 Abstract 
 Background/Aims: Hippocampal atrophy is a recognized biomarker of Alzheimer disease 
(AD) pathology. Serum brain-derived neurotrophic factor (BDNF) reduction has been associ-
ated with neurodegeneration. We aimed to evaluate BDNF serum levels and hippocampal 
volume in clinical AD (dementia and mild cognitive impairment [MCI]).  Methods: Participants 
were 10 patients with MCI and 13 with dementia due to AD as well as 10 healthy controls. 
BDNF serum levels were determined by ELISA and volumetric measures with NeuroQuant ® . 
 Results: MCI and dementia patients presented lower BDNF serum levels than healthy par-
ticipants; dementia patients presented a smaller hippocampal volume than MCI patients and 
healthy participants.  Discussion: The findings support that the decrease in BDNF might start 
before the establishment of neuronal injury expressed by the hippocampal reduction. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction  
 Alzheimer disease (AD) is associated with hippocampal atrophy and memory decline  [1, 
2] . Memory impairment is one of the most common symptoms in patients in the early stages 
of AD; it is characterized by explicit memory deficit, particularly episodic and working 
 Published online: December 9, 2016 
E X T R A
 Márcia L.F. Chaves 
 Rua Ramiro Barcelos, 2350, sala 2040 
 Porto Alegre, RS 90035-091 (Brazil) 
 E-Mail mchaves  @  hcpa.edu.br 
 
www.karger.com/dee
 DOI: 10.1159/000450601 
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Interna-
tional License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribu-




























560Dement Geriatr Cogn Disord Extra 2016;6:559–567
 DOI: 10.1159/000450601 
E X T R A
 Borba et al.: Brain-Derived Neurotrophic Factor Serum Levels and Hippocampal 
Volume in Mild Cognitive Impairment and Dementia due to Alzheimer Disease  
www.karger.com/dee
© 2016 The Author(s). Published by S. Karger AG, Basel
memory functions  [3] . These deficits are reflective of the involvement of the hippocampal 
formation  [4] . Impaired verbal and episodic memory were correlated with reduced volume 
of the hippocampal formation and entorhinal cortex, which may be reduced by 25% using 
volumetric scanning  [5] . Atrophy was most marked in the entorhinal cortex and superior 
temporal gyrus and extended to the anterior cingulate  [5] .
 Recently, there has been a conceptual shift towards the proposal that AD exists before 
the onset of dementia  [6] . Therefore, a clinical phenotype of memory/cognitive impairment 
without significant functional impairment, called mild cognitive impairment (MCI), was 
included in the diagnostic criteria of the International Working Group  [7] and the National 
Institute of Aging-Alzheimer’s Association (NIA-AA)  [6] . The NIA-AA criteria also proposed 
several biomarkers to support this predementia or prodromal AD diagnosis. Among these 
biomarkers, structural neuroimaging with atrophy of the medial temporal region as positive 
diagnostic information was included. Combinations of distinct biomarkers, including hippo-
campal volumetry, present a good predictive value to differentiate AD from normal aging in 
patients with MCI  [6] .
 Brain-derived neurotrophic factor (BDNF), a neurotrophin highly expressed in the hippo-
campus  [8] , is a vital component of synaptic plasticity and memory formation  [9, 10] . BDNF 
has been related to hippocampal plasticity  [9, 11] and its action plays a central role in the 
mechanism of long-term potentiation – one of the most accepted models for memory forma-
tion – resulting in structural synaptic changes  [9, 10] . However, despite all the available infor-
mation, there is no consensus about the serum BDNF profile in neurodegenerative diseases, 
particularly AD. While some studies have reported lower BDNF serum levels in AD patients 
in comparison with healthy subjects  [12–14] , other studies demonstrated higher BDNF serum 
levels in AD individuals  [15] or no difference between AD and controls  [16] . 
 Likewise, studies on cerebrospinal fluid (CSF) BDNF levels in AD and other dementias 
report conflicting results. Forlenza et al.  [17] demonstrated decreased CSF BDNF concen-
tration associated with progression to AD in amnestic MCI patients. Blasko et al.  [18] did not 
find a significant difference in BDNF between AD and controls, and Laske et al.  [19] showed 
lower CSF BDNF concentrations among AD patients in comparison to healthy controls and 
non-AD dementia patients. Furthermore, a study with healthy older adults showed an asso-
ciation of lower CSF BDNF levels with poorer memory performance and faster cognitive 
decline  [20] .
 The effect of the BDNF genetic variability or circulating levels of BDNF on memory and 
hippocampal volume in healthy older adults and in individuals with MCI or early dementia 
has also been evaluated showing discrepant results. Among individuals with amnestic MCI 
and high amyloid-β accumulation, BDNF Val66Met carriers showed a significant and larger 
decline in episodic memory and hippocampal volume  [21] . A significant correlation between 
lower circulating BDNF and memory deficit was demonstrated in a cohort with MCI partici-
pants  [14] . BDNF serum levels and hippocampal volume were found to positively correlate in 
a study with healthy older adults  [22] , but this relation was not further observed  [23] . Addi-
tionally, no significant BDNF effect, in terms of genotype or plasma, in both hippocampal 
volume and memory was found in 2 large independent middle- and old-age cohorts of cogni-
tively normal and early-stage dementia participants  [24] . Finally, aging itself is associated 
with reduced hippocampal volume, lower levels of serum BDNF, and poorer memory perfor-
mance  [22] .
 Therefore, the objective of the study was the evaluation of BDNF serum levels and hippo-
campal volume in individuals with MCI and dementia due to AD, as well as in healthy elderly 
participants. The relationship between BDNF serum levels and hippocampal volume was also 
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 Methods 
 Participants 
 The sample was composed of 10 healthy elderly individuals, 10 participants with MCI, 
and 13 with dementia due to AD. Healthy elderly individuals were community-dwelling resi-
dents who were accompanying Internal Medicine patients, were functionally independent, 
and presented a Mini-Mental State Examination (MMSE) score >26, cognitive performance 
above the cutoffs for this population, and a Clinical Dementia Rating Scale score of 0. The 
NIA-AA core clinical criteria for MCI due to AD were used to identify the MCI group: (1) 
cognitive concern reflecting a change in cognition reported by the patient or informant or 
clinician (i.e., historical or observed evidence of decline over time); (2) objective evidence of 
impairment in 1 or more cognitive domains, typically including memory (i.e., formal or 
bedside testing to establish level of cognitive function in multiple domains); (3) preservation 
of independence in functional abilities; and (4) not demented. In addition, vascular, trau-
matic, medical causes of cognitive decline and the autosomal dominant form of AD were ruled 
out by clinical history  [6] . All dementia patients met the NIA-AA criteria for probable dementia 
due to AD  [25] . Patients (MCI and dementia) were selected from the Dementia Outpatient 
Clinic of the Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
 All subjects underwent a clinical history and physical examination, the MMSE  [26, 27] , 
the Clinical Dementia Rating Scale  [28–30] , the Activities of Daily Living and Instrumental 
Activities of Daily Living functional scales  [31] and a multidomain cognitive evaluation. This 
cognitive battery assessed episodic memory, executive function, attentional control, visuo-
spatial skills and language by the Rey Auditory Verbal Learning Test  [32] , the figure copying 
and the CERAD word list test  [33] , the clock-drawing test  [34] , the Trail Making Test  [35] , the 
digit span forward  [36] , and the letter and category fluency  [37] . The available age and educa-
tional norms were considered to evaluate the scores of each test.
 All participants and/or a proxy gave written informed consent and all procedures were 
approved by the Hospital de Clínicas de Porto Alegre Research Ethics Committee (# 110275).
 BDNF Measurement 
 Blood nonfasting samples were collected in serum-separating tubes during clinical eval-
uations, centrifuged, aliquoted, and stored at –80 ° C.
 BDNF levels in serum samples were determined by sandwich ELISA using monoclonal 
antibodies specific for BDNF (R&D Systems, Minneapolis, MN, USA). Briefly, microtiter plates 
were coated overnight at room temperature with the monoclonal anti-BDNF antibody at 4 μg/
mL in PBS. Then, plates were washed 3 times with wash buffer and blocked for 1 h at room 
temperature with PBS containing 5% nonfat milk powder. After washing, plates were coated 
overnight at 4 ° C with the samples diluted 1: 200 in sample diluent (PBS with 1% BSA) and the 
standard curve ranged from 7.8 to 500 pg/mL of BDNF. Plates were washed again and bioti-
nylated anti-BDNF antibody at 0.2 μg/mL in PBS was added, which was incubated for 2 h at 
room temperature. After washing, incubation with streptavidin-peroxidase conjugate (diluted 
1: 1,000 in sample diluent) for 1 h at room temperature was performed. Plates were washed 
and incubated with the substrate for 20 min at room temperature. Finally, the stop solution 
was added and the amount of BDNF was determined by absorbance at 450 nm. The standard 
curve demonstrated a direct relationship between optical density and BDNF concentration.
 Magnetic Resonance Imaging Acquisition 
 Magnetic resonance imaging (MRI) data were obtained in a Philips Achieva 1.5-Tesla 
scanner (Amsterdam, the Netherlands). T1 high-resolution sagittal 3D magnetization-
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232, flip angle = 8°, TE = 4 ms, TR = 8.63 ms, and voxel size = 1 × 1 × 1 mm 3 yielding 160 slices. 
Axial fluid-attenuated inversion recovery was acquired with TR = 11,000 ms, TE = 140 ms,
TI = 2,800 ms, turbo factor = 55, EPI factor = 1, NEX = 3, slice thickness = 5 mm, and matrix = 
186 × 512 providing pixel measurements of 1 × 0.86 mm given the 220 × 220 mm field of view. 
Study time for this version of fluid-attenuated inversion recovery was 2 min and 56 s.
 Volumetric Analysis 
 We obtained volumetric measurements from the high-resolution anatomic images using 
NeuroQuant ® (CorTechs Labs Inc., San Diego, CA, USA), which is a fully automated program 
that has been validated against other segmentation procedures and found sensitivity to volu-
metric changes in mild AD  [38] and MCI  [39] . This program provides volumes for 2 medial 
temporal lobe regions (hippocampus and inferior lateral ventricles). NeuroQuant (auto-
mated) analyzes 3D MRI scans offering accurate, consistent, and reproducible measures and 
segmentations of brain subcortical structures comparing them with standardized values 
according to age, sex and cranial volume. The NeuroQuant computer-automated analysis 
routinely provides volume data on 9 brain regions, left and right sides, for a total of 18 volume 
measurements (http://www.cortechs.net/products/neuroquant.php). For the present study, 
we only used the hippocampal and the forebrain parenchyma volumes. The volume of the 
hippocampus was analyzed as the sum of the right and left hippocampus (total volume), as 
well as the forebrain parenchyma (total volume).
 Statistical Analysis 
 Statistical analyses were performed using PASW Statistics 18.0 for Windows (SPSS, 
Chicago, IL, USA). Descriptive statistics (mean, SD and frequency) were calculated for demo-
graphic, cognitive and MRI data. The χ 2 test with the Fisher exact test were used for cate-
gorical variables, and the Spearman nonparametric correlation was also performed. ANCOVA 
was used for the analyses controlling for age as covariate. The Bonferroni test was used for 
the post hoc comparisons.
 Results 
 Demographic and clinical data are presented in  Table 1 . Dementia patients were signifi-
cantly older than MCI and healthy subjects. Moreover, they presented lower MMSE and higher 
Clinical Dementia Rating Scale Sum of Boxes scores.








Age, yearsa 68.60 ± 4.62 69.20 ± 7.88 76.08 ± 6.08* 0.012
Female, n (%)b 6 (60%) 6 (60%) 10 (76.9%) 0.602
Education, yearsa 12.20 ± 6.37 9.60 ± 6.07 6.92 ± 6.17 0.145
CDR-SBa 0.24 ± 1.14 1.39 ± 1.13 7.43 ± 1.06** 0.001
MMSE scorea 28.85 ± 1.14** 24.88 ± 1.12** 16.63 ± 1.05** 0.001
 CDR-SB, Clinical Dementia Rating Scale Sum of Boxes; MMSE, Mini-Mental State Examination. a One-way 
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 Table 2 shows the comparison of BDNF serum levels, hippocampal and forebrain paren-
chyma volumes among the 3 groups. Healthy participants had higher BDNF levels ( p < 0.001) 
than dementia and MCI patients. The dementia group presented a significantly lower total 
hippocampal volume than MCI and healthy participants ( p < 0.001), while the 2 latter groups 
did not differ. No significant difference in the total forebrain parenchyma volume (cm 3 ) 
among the groups was observed. All analyses were age-adjusted. 
 To strengthen the results, the correlation analysis was carried out in the whole sample, 
allowing higher variability of each variable and a larger sample size. However, no significant 
correlation of serum BDNF with hippocampus volume was observed (Spearman rho = –0.04; 
 p = 0.87).
 Discussion 
 The present study was carried out to evaluate BDNF serum levels and hippocampal 
volume in healthy elderly participants and in patients with MCI and dementia due to AD 
according to the NIA-AA criteria  [6, 25] . We also aimed to analyze the correlation of serum 
BDNF and hippocampal volume in the whole sample. We have hypothesized a decreasing 
gradient of BDNF serum levels and hippocampal volume from healthy participants toward 
MCI and dementia due to AD, based on the following assumptions: (a) BDNF plays a central 
role in long-term memory potentiation mechanism  [9, 10] ; (b) memory impairment is an 
early and typically clinical phenotype of AD pathology  [6, 7] ; (c) episodic memory impairment 
and hippocampal volume reduction are associated  [1–3, 40] ; and (d) hippocampal volumetry 
was included in the set of biomarkers proposed to differentiate AD from normal aging in 
patients with MCI. We also hypothesized a relation of BDNF levels with hippocampus volume, 
taking into account the high expression of BDNF in the hippocampus  [8] and its relation with 
hippocampal plasticity  [9, 11] . Our main findings are: (1) healthy participants present signif-
icantly higher BDNF serum levels than patients with MCI and dementia due to AD; (2) 
dementia patients present a significantly smaller hippocampal volume than MCI and healthy 
participants; and (3) BDNF serum levels do not correlate with hippocampal volume. Therefore, 
our prior hypotheses were partially confirmed.
 Healthy participants presented higher BDNF serum levels than MCI and dementia 
patients. Patients with MCI and those with dementia due to AD presented similar levels. Our 
findings are similar to the group of studies reporting higher BDNF levels in healthy elderly 
individuals and reduced levels in MCI and AD patients  [12–14, 24, 41] . However, there is no 
consensus on the pattern of serum BDNF in these conditions, because another set of studies 
reported higher  [15, 42] or similar BDNF levels  [16, 43, 44] in patients with AD. Nonetheless, 
 Table 2. Age-controlled comparison of BDNF serum levels and MRI volumetric data among studied groups 









BDNF level, pg/mL 26.25 ± 2.90* 20.57 ± 2.93 14.59 ± 2.75 3.72 0.036
Forebrain parenchyma volume, cm3 949.80 ± 27.22 926.40 ± 26.86 860.55 ± 25.21 2.73 0.082
Total hippocampal volume, cm3 6.48 ± 0.23 6.29 ± 0.26 4.91 ± 0.24** 9.74 0.001
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our findings support the reduction of serum BDNF in neurodegenerative disease, such as MCI 
and dementia due to AD. In the study of Forlenza et al.  [17] , reduced CSF BDNF concentrations 
predicted progression of MCI to AD, suggesting the involvement of BDNF in the pathophysi-
ology of neurodegenerative changes in AD.
 Analyzing brain volumes, we found a higher hippocampal than forebrain reduction 
among dementia patients, but not among MCI and healthy participants, emphasizing the 
disproportional atrophy of these regions in mild stages of dementia due to AD (according to 
the Clinical Dementia Rating Scale Sum of Boxes distribution). The specific hippocampal 
atrophy in AD has already been encompassed by the NIA-AA diagnostic criteria recommen-
dation as a structural biomarker of early AD pathology and a predictor of progression  [6, 25, 
45] . Looking particularly at the MCI findings, no significant difference in hippocampal volume 
was found as compared to healthy participants. This could be explained by the use of the 
NIA-AA MCI core clinical criteria in the present investigation, a syndrome defined by clinical, 
cognitive, and functional criteria. The NIA-AA group reported that, similar to dementia due to 
AD, other etiologies in addition to the AD pathophysiological process may coexist in an indi-
vidual who meets the criteria for MCI due to AD  [6] . Such heterogeneity could have impacted 
the progression of neuronal injury, measured by the volume of the hippocampus, in our MCI 
patients. Although MCI clinical criteria are recommended to be applied in clinical settings, 
they are different from MCI research criteria which include a set of neuroimaging and CSF 
biomarkers  [6] . Among these biomarkers, hippocampal volumetry is one of them. Then, 
starting with the clinical identification of cases we cannot expect full biomarker positivity in 
all MCI patients. Levels of certainty according to the presence and nature of the biomarker 
findings were also proposed for the final set of criteria for MCI due to AD  [6] . Finally, although 
the automated program used as segmentation procedure for the volumetric measures is valid 
and sensitive  [38, 39] , automated hippocampal segmentation algorithms need to be validated 
against the manual segmentation gold standard  [46] .
 It is accepted that reduced BDNF serum levels may correspond to the lack of neuro-
trophic support due to increased amyloid-β accumulation contributing for the progressive 
degeneration of specific brain regions affected by Alzheimer pathology  [19] . Taking our 
results together (lower BDNF levels in MCI and dementia due to AD and smaller hippocampal 
volume in dementia due to AD), we can hypothesize that the decrease in BDNF may start 
before the establishment of neuronal injury expressed by the hippocampal reduction.
 The BDNF can cross the blood-brain barrier in both directions and BDNF in the blood and 
in the cerebral cortex showed a positive correlation in animal studies  [47, 48] . The hippo-
campus is one of the main regions of BDNF expression in the cerebral cortex, supporting the 
a priori hypothesis of the present study. However, our findings refute this hypothesis since 
no relationship of BDNF serum levels with hippocampal volume was found. Therefore, serum 
BDNF did not seem a consistent marker for hippocampal atrophy. 
 In agreement with our result, another investigation showed BDNF serum levels reflecting 
some aspects of neuronal integrity, although no significant relationship between BDNF serum 
concentrations and any hippocampal brain metabolites were observed  [49] . Furthermore, we 
did not analyze the effect of the variation of the BDNF gene (Val66Met substitution) on the 
hippocampus volume as already explored. However, these studies are not conclusive since 
some showed an association  [50] or no relation of this genetic variability or of the BDNF-
circulating levels with the hippocampus volume in healthy and early dementia subjects  [24] . 
An early effect of the reduction of BDNF on hippocampal volume, i.e. neuronal injury, would 
be another possibility to explain this finding.
 The current study has limitations such as the small sample size and the cross-sectional 
design preventing another data approach as well as the longitudinal assessment of these 
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comparison of BDNF levels and hippocampal volume in the 3 groups was age-adjusted, since 
age alone can affect the hippocampal volume, serum BDNF, and memory performance  [22] . 
In addition, the use of neuropsychological tests such as the Rey Auditory Verbal Learning test 
to measure episodic memory impairment (i.e., the ability to acquire and retain new infor-
mation), which have age and gender norms for the Brazilian population, provided higher reli-
ability in establishing the clinical AD phenotype.
 Finally, this is an exploratory investigation that supports the role of reduced BDNF serum 
levels (easily measurable) in amnesic phenotypes, as well as the established neuronal injury 
detected by the hippocampal loss in dementia due to AD. The relation of circulating BDNF 
with hippocampal volume was not observed, but this issue deserves further investigation 
with larger samples, a longitudinal design and BDNF cerebrospinal measures. 
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